Bullous pemphigoid - Pipeline Insight, 2021

Publisher Name :
Date: 12-Oct-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Bullous pemphigoid - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Bullous pemphigoid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Bullous pemphigoid Understanding

Bullous pemphigoid: Overview

Bullous pemphigoid (BP) is a rare, autoimmune, chronic skin disorder characterized by blistering, urticarial lesions (hives) and itching. Less commonly these blisters can involve the mucous membranes including the eyes, oral mucosa, esophagus and genital mucosa. It typically presents in older adults as a generalized intensely itchy blistering skin condition. The first symptom of BP is usually redness and itching of the skin. Within weeks to months, thin-walled, tense blisters with clear fluid centers (bullae) appear on the arms and legs (flexor surfaces), in the armpits (axillae), on the abdomen, and/or in the skinfolds of the groin. Mucous membranes may also be involved but are less commonly seen than skin blisters.

"Bullous pemphigoid - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bullous pemphigoid pipeline landscape is provided which includes the disease overview and Bullous pemphigoid treatment guidelines. The assessment part of the report embraces, in depth Bullous pemphigoid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bullous pemphigoid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.

Bullous pemphigoid Emerging Drugs Chapters

This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bullous pemphigoid Emerging Drugs

- Benralizumab: AstraZeneca

Interleukin-5 (IL-5) induces an eosinophil-mediated inflammatory response by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Benralizumab, unlike IL-5 low-affinity binding, binds with high affinity to the domain I of the ?-chain of IL-5R and blocks its signaling and the proliferation of IL-5-dependent cell lines. On the other hand, Benralizumab is an afucosylated antibody in the CH2 region which gives it a high affinity for the Fc?RIIIa on natural killer cells, macrophages and neutrophils. This binding triggers a magnified apoptosis response in eosinophils via antibody-dependent cell-mediated cytotoxicity. Currently, it is in Phase III stage of clinical trial evaluation to treat Bullous Pemphigoid.

- Dupilumab: Regeneron/Sanofi

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor ? (IL-4R?) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. The drug is in Phase III clinical studies for Bullous Pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. The FDA has granted orphan drug designation to Dupilumab or the treatment of Bullous Pemphigoid.

Further product details are provided in the report……..

Bullous pemphigoid: Therapeutic Assessment

This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Bullous pemphigoid

There are approx. 8+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

- Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Bullous pemphigoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravenous

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bullous pemphigoid: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bullous pemphigoid therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bullous pemphigoid drugs.

Bullous pemphigoid Report Insights

- Bullous pemphigoid Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Bullous pemphigoid Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Bullous pemphigoid drugs?

- How many Bullous pemphigoid drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Bullous pemphigoid and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- AstraZeneca

- Regeneron

- Alkahest

- Akari Therapeutics

- Immune Pharmaceuticals

- Eli Lilly and Company

- Amgen

- TWi Biotechnology

Key Products

- Benralizumab

- Dupilumab

- Lazucirnon

- Nomacopan

- Bertilimumab

- Ixekizumab

- Apremilast

- Diacerein

Bullous pemphigoid - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Bullous pemphigoid: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Bullous pemphigoid - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
* Comparative Analysis
Benralizumab: AstraZeneca
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
Lazucirnon : Alkahest
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
Sutimlimab: Bioverativ
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
* Comparative Analysis
Bullous pemphigoid Key Companies
Bullous pemphigoid Key Products
Bullous pemphigoid- Unmet Needs
Bullous pemphigoid- Market Drivers and Barriers
Bullous pemphigoid- Future Perspectives and Conclusion
Bullous pemphigoid Analyst Views
Bullous pemphigoid Key Companies
Appendix

List of Tables

Table 1 Total Products for Bullous pemphigoid
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Bullous pemphigoid
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • China Ocular Drug Delivery Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 91
    China Ocular Drug Delivery Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Type, 2020 (%) - Ocular Insert - Iontophoresis - Intraocular Implants - In Situ Gel & Punctal Plugs - Others China Ocular Drug Delivery Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Application, 2020 (%)......
  • China Nuclear Medicine/Radiopharmaceutic Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 93
    China Nuclear Medicine/Radiopharmaceutic Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment Percentages, By Type, 2020 (%) - Tc-99 - I-123/131 - In-111 - Xe-133 - Th-201 - Ga-67 - Other China Nuclear Medicine/Radiopharmaceutic Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment P......
  • China NSAIDs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China NSAIDs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Type, 2020 (%) - Aspirin - Ibuprofen - Naproxen - Nabumetone - Others China NSAIDs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Application, 2020 (%) - Back Pain Treatment - Osteoarthritis Treatment - Other Disease Treatment......
  • China Non-Tyrosine Kinase Inhibitors Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-Tyrosine Kinase Inhibitors Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Type, 2020 (%) - mTOR Inhibitors - RAF/MEK Inhibitors - CDK Inhibitors China Non-Tyrosine Kinase Inhibitors Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Application, 2020 (%) - Liver Can......
  • China Nonsteroidal Antiinflammatory Drugs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China Nonsteroidal Antiinflammatory Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percentages, By Type, 2020 (%) - Oral Nonsteroidal Antiinflammatory Drugs - Injection Nonsteroidal Antiinflammatory Drugs China Nonsteroidal Antiinflammatory Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percenta......
  • China Non-opioid Pain Patch Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-opioid Pain Patch Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Percentages, By Type, 2020 (%) - Lidocaine Patches - Diclofenac Patches - Indomethacin Patches - Counter-Irritant Patches - Fentanyl Patches - Others China Non-opioid Pain Patch Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Perc......
  • China Non Narcotic Analgesics Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 92
    China Non Narcotic Analgesics Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Type, 2020 (%) - Non Steroid Antiinflammatory Drug - Steroid Antiinflammatory Drug China Non Narcotic Analgesics Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Application, 2020 (%) - Hospital - Medical Center......
  • Global Azelastine Nasal Spray Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 100
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 0.137MG/SPRAY - 0.2055MG/SPRAY - Other Segment by Application - Hospital - Ret......
  • Global Azelastine Drug Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 114
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nasal Spray - Eye Drops - Other Segment by Application - Hospital - Retail Pha......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs